Clinical Trials Browser

Phase 2/3 × Advanced Cancers × Clear all

NCT02597478 2021-02-09

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

Phase 2/3 Completed

50 enrolled 14 charts

Advanced Cancers